New York State Teachers Retirement System Has $130.23 Million Holdings in Pfizer Inc. $PFE

New York State Teachers Retirement System decreased its holdings in Pfizer Inc. (NYSE:PFE) by 0.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,637,857 shares of the biopharmaceutical company’s stock after selling 26,141 shares during the period. New York State Teachers Retirement System owned about 0.08% of Pfizer worth $130,231,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in PFE. Brighton Jones LLC grew its position in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its position in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares in the last quarter. United Bank raised its position in shares of Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 6,415 shares in the last quarter. Sei Investments Co. boosted its stake in shares of Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after buying an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC grew its position in Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after buying an additional 31,896 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. CICC Research assumed coverage on Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. Guggenheim upped their target price on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. UBS Group reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Morgan Stanley boosted their price target on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Finally, Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Stock Up 1.7%

Shares of PFE opened at $24.29 on Friday. The firm has a 50 day simple moving average of $25.68 and a two-hundred day simple moving average of $26.24. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company has a market cap of $138.45 billion, a P/E ratio of 18.54 and a beta of 0.35.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter last year, the business posted $0.92 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. Pfizer’s dividend payout ratio is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.